Hinge Health HNGE is well-positioned for sustained growth, driven by robust revenue growth, expanding opportunities in Migraine and gastrointestinal (GI) care and a scalable AI-powered MSK platform. The raised 2026 outlook, broader enterprise reach and growing sales pipeline further support the growth outlook. However, continued investments and Cylinder Health integration could weigh on margin expansion.
This Zacks Rank #3 (Hold) company’s shares have surged 88.2% in the year-to-date period compared with the 2.4% growth of the industry. The S&P 500 Composite has increased 12.8% during the said time frame.
The digital MSK care provider has a market capitalization of $6.68 billion. The company anticipates 31.6% growth for the next year and expects to maintain its strong performance in the future. It delivered a trailing four-quarter average earnings surprise of 18.4%.
Image Source: Zacks Investment Research
Reasons Favoring HNGE’s Growth
Guidance Raise Reinforces Growth Outlook: Hinge Health’s second-quarter 2026 revenues jumped 53% year over year to $212.8 million, while LTM calculated billings rose 52% to $862 million, aided by stronger yields. Management raised 2026 revenue guidance to $856-$860 million and non-GAAP operating income guidance to $236-$244 million, implying a 28% margin at the midpoint. Third-quarter revenues are projected to be in the range of $223-$225 million, reflecting 45% growth at the midpoint and underscoring the improving contribution from enrolment, referrals and renewals.
Expanding Beyond Core MSK: Hinge Health is broadening its addressable market by applying its technology and distribution network to Migraine and GI care, with opportunities estimated at $78 billion and $135 billion, respectively. Migraine adoption surged to more than 450 clients covering over 5 million eligible lives in the second quarter.
Hinge Health is also acquiring Cylinder Health for $105 million to accelerate its GI expansion, adding nearly 100 clients across 2 million lives. The deal is expected to contribute $7-$8 million in 2026 revenues, with a broader rollout planned for 2027, creating additional wallet-share opportunities across Hinge Health’s existing client base.
Strong Q2 Results: Hinge Health delivered a strong second-quarter 2026 performance, supported by higher member yield, robust billings growth, margin expansion and a growing client base. Product expansion remains a key growth driver, with Migraine Care reaching more than 450 clients and 5 million lives, while the $105 million Cylinder Health acquisition expands HNGE into GI care. Improving win rates, a healthy sales pipeline and broader health-plan distribution further strengthen its land-and-expand strategy and support sustained growth.
A Factor That May Offset HNGE’s Gains
Reinvestment and Integration Can Temper Operating Leverage:Hinge Health continues to fund product expansion even as margins rise. Second-quarter 2026 GAAP operating expenses were $143.5 million, including $81.4 million of sales and marketing and $34.1 million of R&D. The planned $105 million Cylinder Health acquisition adds integration work, and management has said that GI will require investment before a broader 2027 rollout. Cylinder is expected to contribute only $7-$8 million of 2026 revenues after closing. Although full-year non-GAAP operating margin guidance increased to 28% at the midpoint, a faster build-out of GI, Migraine or other programs could reduce the pace of margin expansion.
Estimate Trend
Hinge Health is witnessing a negative estimate revision trend for 2026. In the past 30 days, the Zacks Consensus Estimate for 2026 earnings per share (EPS) has moved south 2 cents to $2.50.
The Zacks Consensus Estimate for third-quarter 2026 revenues is pegged at $225.2 million, indicating a 46.1% improvement from the year-ago quarter’s reported number. The EPS estimate for the third quarter of 2026 is pinned at 67 cents, implying a 97.1% improvement year over year.
Key Picks
Some better-ranked stocks in the broader medical space are McKesson MCK, Phibro Animal Health PAHC andCardinal Health CAH.
McKesson carries a Zacks Rank #2 (Buy) at present and has an estimated long-term growth rate of 13.7%. MCK’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 3.09%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
McKessonshares have gained 8.8% against the industry’s 12.7% decline in the year-to-date period.
Phibro Animal Health, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 21.5%. PAHC’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 16.25%.
Phibro Animal Health stock has climbed 44.2% against the industry’s 17.1% decline in the year-to-date period.
Cardinal Health, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 17%. CAH’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 10.27%.
Cardinal Health’s shares have lost 2.6% compared with the industry’s 3.1% decline in the year-to-date period.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
(0) comments
Welcome to the discussion.
Log In
Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
PLEASE TURN OFF YOUR CAPS LOCK.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
Share with Us. We'd love to hear eyewitness accounts, the history behind an article.